Table 1.
Clinical and demographic data for validation cohort (n = 41)
| Variable | n (%) | Mean (s.d.) | Median (range) |
|---|---|---|---|
| Demographics | |||
| Females | 29 (71) | ||
| Males | 12 (29) | ||
| Age, years | 16 (3) | 16 (7–26) | |
| Hispanics/non-Hispanics | 5 (12) | ||
| 36 (88) | |||
| White/Black/Asian | 20 (49) | ||
| 20 (49) | |||
| 1 (2) | |||
| Disease activity | |||
| Extrarenal SLEDAI | 3.85 (4.57) | 2 (0–17) | |
| Renal SLEDAI | 6.93 (6.2) | 8 (0–16) | |
| LN | |||
| ISN/RPS Class of LNa | II 3 (8.3%) | ||
| III 7 (19.4%) | |||
| IV 17 (47.2%) | |||
| V 9 (25%) | |||
| NIH Activity Scorea | 8.66 (6.53) | 9 (0–22) | |
| NIH Chronicity Scorea | 2.02 (1.52) | 2 (0–6) | |
| Creatinine clearanceb, mg/ml/1.73 m2 | 109.56 (54.46) | 95.23 (21.1–228.2) | |
| Protein creatinine ratiob | 4.01 (7.06) | 2.25 (0.01–42.5) | |
a
No biopsy information on five patients given clinical absence of LN, activity and chronicity scores of 0 assigned for purpose of analysis.
b
Information missing on one patient. ISN/RPS: International Society of Nephrology/Renal Pathology Society; NIH: National Institutes of Health.